FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Harrow launches Vigamox in US
This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.
Corneal cross-linking effective for keratoconus relapse after penetrating keratoplasty
A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.
FDA issues CRL for aflibercept 8 mg from Regeneron Pharmaceuticals
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Glaukos achieves pipeline milestone with enrollment completion in phase 3 confirmatory trial for Epioxa
The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.
Lumata Health and Prevent Blindness partner to provide more resources
Vlog: Eye stroke evaluations have changed positively, reducing inappropriate outpatient or incomplete workups
On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss the current status of eye stroke evaluations for CRAO.
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
Commercial real estate and your practice, part two with Colin Carr
On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the Q&A with Ophthalmology Times® executive editor, David Hutton.
Recent research suggests amblyopia has an affect on binocular vision
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
Study: Keratoconus patients experience challenges in getting timely corneal crosslinking that has led to permanent changes in their corneal structure
The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Carr hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.
Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
New advancements in IOL technology is exciting for presbyopia treatment
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
ARMOR study evaluates antibiotic resistance in the treatment of staph infections
Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
Study evaluates OC-01 (varenicline solution) as a treatment for symptoms and signs of dry eye
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
Cell therapy trial shows promising results for patients with advanced dry AMD
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
Dexamethasone plug opens opportunity for treatment that will bring patients relief, help alleviate and mitigate the signs and symptoms associated with conjunctivitis from allergies
A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.
New noninvasive technology shows positive safety and efficacy for the treatment of open angle glaucoma
Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.
Patricia Bath, MD, inducted into the National Inventors Hall of Fame
Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.
Cataract classification method allows for higher success rates of cataract surgery
Alex Dastgheib, MD, ABO, discusses the findings of the paper, "325 Cases of Phacoemulsification in Blind Cataracts," presented at the 2022 ASCRS conference in Washington, DC. The paper won the Challenging Cases session during the meeting.
Beyeonics One exoscope offers an immersive experience that allows for better patient and surgeon outcomes
Jonathan Solomon, MD, shares his personal experience using the Beyeonics One exoscope, highlighting what makes this tool stand out.
Retrospective study shows toric IOL rotation rate to be low at 2.1%
Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.
Aerie Pharmaceuticals continues their work in dry eye and glaucoma markets
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.
Johnson & Johnson Surgical Vision (JJV) continues innovation through new and elevated technologies
Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.
Tarsus announces positive topline data of TP-03 from Saturn-2 Phase 3 trial, expects to file NDA later this year
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
Riad Sherif, CEO of Oculis, gives a company update on clinical trials, financing and other items in the pipeline
Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.
ViaLase technology could impact glaucoma care for patients worldwide
Kevin Waltz, a consultant for ViaLase, discusses the company's technology: an image-guided femtosecond laser surgical system for the treatment of glaucoma.
Findings help investigators understand how FDA-approved AGN-19058 behaves
George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.
2 Clarke Drive Cranbury, NJ 08512